A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer

被引:7
作者
Dorjee, Penpa [1 ,2 ,3 ]
Long, Zi-Wen [1 ,2 ,3 ]
机构
[1] Shigatse Peoples Hosp, Dept Med, Shigatse, Peoples R China
[2] Fudan Univ, Dept Gastr Canc & Soft Tissue Sarcoma Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China
[3] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
关键词
Bayesian network meta-analysis; Hematotoxicity; Non-hematotoxicity; Pancreatic cancer; Randomized controlled trials; Targeted drugs; PHASE-III TRIAL; ERLOTINIB PLUS GEMCITABINE; ORAL MEK INHIBITOR; RANDOMIZED-TRIAL; DOSE-ESCALATION; DOUBLE-BLIND; EFFICACY; PLACEBO; METAANALYSIS; COMBINATION;
D O I
10.1080/15384047.2018.1433503
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mixed treatment comparison study was performed in order to compare the toxicities of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic pancreatic cancer (PC). Searches were performed from the inception of PubMed and Cochrane Library databases to February 2017. This study included randomized controlled trials (RCTs) of Gemcitabine and different targeted drug combinations in the treatment of advanced/metastatic PC. Odds ratio (OR) values were calculated by direct and indirect comparisons, and the surface under the cumulative ranking curves (SUCRA) were drawn. A total of six RCTs were finally incorporated into the study. These studies included six therapy regimens: Gemcitabine + Axitinib, Gemcitabine + Trametinib, Gemcitabine + Sorafenib, Gemcitabine + Bevacizumab, Gemcitabine + Erlotinib and Gemcitabine + Tipifarnib. The results showed that Gemcitabine + Axitinib combinations showed lower incidence rates of rashes (all grades) in comparison to Gemcitabine + Trametinib and Gemcitabine + Erlotinib combinations. Compared with Gemcitabine+ Trametinib combinations, Gemcitabine + Axitinib combinations showed lower incidence rates of diarrhea (grade >= 3). Moreover, the cluster analyses results revealed that Gemcitabine + Axitinib combinations and Gemcitabine + Sorafenib combinations showed lower incidence rates of hematotoxicity, while Gemcitabine + Axitinib combinations showed lower incidence rates of non-hematotoxicity. Collectively, the data provided strong evidence of Gemcitabine + Axitinib combinations showing lower incidence rates of non-hematotoxicity, and Gemcitabine + Axitinib and Gemcitabine + Sorafenib combinations may have lower incidence rates of hematotoxicity in the treatment of advanced/metastatic PC.
引用
收藏
页码:497 / 506
页数:10
相关论文
共 28 条
[1]   Drugs in preclinical and early-stage clinical development for pancreatic cancer [J].
Asuthkar, Swapna ;
Rao, Jasti S. ;
Gondi, Christopher S. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) :143-152
[2]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[3]   Graphical Tools for Network Meta-Analysis in STATA [J].
Chaimani, Anna ;
Higgins, Julian P. T. ;
Mavridis, Dimitris ;
Spyridonos, Panagiota ;
Salanti, Georgia .
PLOS ONE, 2013, 8 (10)
[4]   Comparative Efficacy and Tolerability of Three Treatments in Old People with Osteoporotic Vertebral Compression Fracture: A Network Meta-Analysis and Systematic Review [J].
Chen, Ling-Xiao ;
Li, Yu-Lin ;
Ning, Guang-Zhi ;
Li, Yan ;
Wu, Qiu-Li ;
Guo, Jin-Xiu ;
Shi, Hong-Yu ;
Wang, Xiao-Bo ;
Zhou, Yong ;
Feng, Shi-Qing .
PLOS ONE, 2015, 10 (04)
[5]   Assessing the Quality of Randomized Controlled Urological Trials Conducted by Korean Medical Institutions [J].
Chung, Jae Hoon ;
Lee, Seung Wook .
KOREAN JOURNAL OF UROLOGY, 2013, 54 (05) :289-296
[6]   Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis [J].
Funakoshi, Tomohiro ;
Suzuki, Maya ;
Tamura, Kazuo .
CANCER TREATMENT REVIEWS, 2014, 40 (10) :1221-1229
[7]   BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer [J].
Goncalves, A. ;
Gilabert, M. ;
Francois, E. ;
Dahan, L. ;
Perrier, H. ;
Lamy, R. ;
Re, D. ;
Largillier, R. ;
Gasmi, M. ;
Tchiknavorian, X. ;
Esterni, B. ;
Genre, D. ;
Moureau-Zabotto, L. ;
Giovannini, M. ;
Seitz, J-F. ;
Delpero, J-R. ;
Turrini, O. ;
Viens, P. ;
Raoul, J-L. .
ANNALS OF ONCOLOGY, 2012, 23 (11) :2799-2805
[8]   Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis [J].
Gresham, Gillian K. ;
Wells, George A. ;
Gill, Sharlene ;
Cameron, Christopher ;
Jonker, Derek J. .
BMC CANCER, 2014, 14
[9]   Systemic treatment of advanced pancreatic cancer [J].
Heinemann, Volker ;
Haas, Michael ;
Boeck, Stefan .
CANCER TREATMENT REVIEWS, 2012, 38 (07) :843-853
[10]   A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [J].
Infante, Jeffrey R. ;
Somer, Bradley G. ;
Park, Joon Oh ;
Li, Chung-Pin ;
Scheulen, Max E. ;
Kasubhai, Saifuddin M. ;
Oh, Do-Youn ;
Liu, Yuan ;
Redhu, Suman ;
Steplewski, Klaudia ;
Le, Ngocdiep .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) :2072-2081